Fentanyl Positivity Is Rising in U.S. Workplaces — What Employers Need to Know

What the Latest Workforce Drug Testing Data Shows

According to the Quest Diagnostics Drug Testing Index, national workforce testing data reveals a significant shift in fentanyl detection patterns:

  • In 2024, fentanyl positivity in the general U.S. workforce was 1.13% in random testing compared to 0.14% in pre-employment testing — more than seven times higher in random testing

  • This trend differs from other drugs. For example, marijuana positivity in random testing has been substantially lower than pre-employment positivity over the past five years

  • Over the same five-year period, fentanyl positivity in random testing has consistently been multiple times higher than in pre-employment testing

  • 60% of fentanyl-positive workforce specimens in 2024 also contained at least one additional drug

  • Marijuana was present in approximately 22% of fentanyl-positive tests, up from about 10% in 2020

  • Amphetamines were detected in 16% of fentanyl-positive tests, compared to 11% in 2020

Source: Quest Diagnostics Drug Testing Index https://www.questdiagnostics.com/business-solutions/insights/drug-testing-index

A Shift That Safety-Sensitive Employers Shouldn't Ignore

One of the most significant changes in workplace drug testing data is the increase in fentanyl positivity.

Analysis from the Quest Diagnostics Drug Testing Index, based on millions of workforce drug tests, shows:

  • Year-over-year increases in fentanyl positivity

  • Significantly higher detection in random testing compared to pre-employment testing

  • Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020

This reinforces a critical operational reality:

  • Pre-employment testing reflects past use

  • Random testing reflects current workforce risk.

Source: Quest Diagnostics Drug Testing Index

Why This Matters for Workplace Safety

Fentanyl is not just another substance on a panel.

According to the CDC, fentanyl use can cause:

  • Extreme drowsiness and sedation

  • Slowed breathing

  • Confusion and impaired judgment

  • Dizziness and loss of coordination

  • Loss of consciousness

Source: https://www.cdc.gov/overdose/prevention/fentanyl.html

In a workplace, these effects directly impact:

  • Reaction time

  • Situational awareness

  • Decision-making

  • Motor control

In safety-sensitive environments, that creates immediate risk for:

  • Vehicle operation

  • Heavy equipment use

  • Working at heights

  • Patient care

  • Energy and utility field work

This is why the conversation is shifting from drug testing as a hiring step → drug testing as an active safety control.

The Most Important Data Point: Random vs. Pre-Employment

The large gap between random and pre-employment positivity tells us:

A workforce can pass pre-hire testing and still develop active substance risk later.

That is why many employers are:

  • Expanding random testing programs

  • Reviewing their panel strategy

  • Standardizing testing across locations

This is not a policy trend — it is a response to real workforce data.

Panel Strategy Is Now a Leadership Decision

Panel design used to be handled as a purchasing decision.

Today it is a:

  • Safety decision

  • Risk management decision

  • Insurance decision

  • Operational decision

Because the key question has changed:

Are we testing for the substances that are actually present in today’s workforce?

What This Means for Multi-Location Employers

For organizations operating across multiple states and facilities, rising fentanyl positivity increases the need for:

  • Consistent testing protocols

  • Faster post-incident response

  • Scalable onsite screening workflows

Programs that are operationally standardized — not just written in policy — are the ones that hold up under growth, audits, and incident investigations.

Observable Signs of Possible Opioid Impairment in the Workplace

For supervisors and safety leaders, the risk is not the drug itself — it is impairment on the job.

These observations must always be documented as behavior and performance indicators — not medical conclusions.

Physical indicators

  • Unusual drowsiness or “nodding off”

  • Slowed movements or delayed reaction time

  • Constricted (pinpoint) pupils

  • Slurred or slowed speech

  • Poor coordination or unsteady walking

  • Drooping eyelids

  • Shallow or slowed breathing

Cognitive and behavioral indicators

  • Confusion or disorientation

  • Difficulty focusing on routine tasks

  • Delayed response to questions

  • Unusual disengagement

  • Sudden performance decline

  • Falling asleep outside of break periods

Sources: https://www.cdc.gov/overdose/prevention/fentanyl.html https://nida.nih.gov/research-topics/opioids

What the Data Shows: Real-World Impact of Drug-Free Workplace Programs

Reduction in workplace injuries

A multi-year analysis of workers’ compensation claims in Washington State found that employers with drug-free workplace programs experienced:

  • Significant reductions in injury rates

  • Fewer injuries involving lost work time

Peer-reviewed source: https://pmc.ncbi.nlm.nih.gov/articles/PMC1360996/

This demonstrates that testing programs function as active safety controls — not just hiring tools.

Workers’ compensation and insurance incentives

In several states, compliant drug-free workplace programs qualify employers for workers’ compensation premium discounts.

Example: https://www.myfloridacfo.com/division/wc/employer/drugfreeworkplace

This reflects how insurers evaluate these programs — as risk reduction strategies.

Deterrence as the primary safety outcome

Under federal regulation, the purpose of random drug testing is to create a deterrent effect.

Source: https://www.law.cornell.edu/cfr/text/49/382.305

For private employers, the same principle applies:

A consistent and well-communicated program changes workforce behavior and reduces incident exposure.

When Employers Typically Review Their Test Panel

In practice, most organizations do not revisit their testing strategy on a calendar.

They do it in response to a trigger event:

  • A serious workplace incident

  • A recommendation from an insurer or broker

  • Expansion into new locations or states

  • A change in workforce risk profile

  • New national positivity data

At that point, panel design becomes a leadership discussion — not a purchasing decision.

Key Takeaway for HR, Safety, and Operations Leaders

The rise in fentanyl positivity is not a future issue.

It is already visible in national workforce data.

And it is changing how employers think about:

  • Random testing

  • Panel design

  • Onsite screening workflows

  • Supervisor training

  • Workforce risk management

Organizations that treat drug testing as a one-time hiring step will fall behind.

Organizations that treat it as an active safety program will adapt.

At My BIO TESTS®, we supply rapid, CLIA-waived drug screening solutions from leading manufacturers to employers implementing onsite workplace testing programs.

Our focus is helping safety-sensitive and multi-location organizations standardize fast, reliable screening workflows with trusted product supply.

If your team is reviewing its testing strategy and evaluating onsite implementation, I’m always happy to connect.

Back to blog